Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Sanofi (SNY - Analyst Report) announced negative top-line phase III data on oncology candidate, iniparib and anticoagulant, otamixaban. Both phase III studies did not meet the primary endpoint. Following the dismal results, the company has decided to discontinue development of both iniparib and otamixaban.

A randomized phase III study (ECLIPSE, n = 780) evaluated the efficacy and safety of iniparib in treatment naïve squamous non-small cell lung cancer patients. The study compared iniparib as an adjunct to Gemzar (gemcitabine)/Paraplatin (carboplatin) versus a Gemzar/Paraplatin regimen. It was found that the addition of iniparib to Gemzar and Paraplatin did not improve the overall survival rate. Additionally, both arms of the study showed similar results in terms of safety.

Moreover, iniparib was also being developed for platinum-resistant ovarian cancer. However, top-line data from a phase II study did not support further progress of the candidate in this indication.

Based on these results, Sanofi has decided to stop development of iniparib.

Meanwhile, a multi-center, randomized, double-blind active-controlled phase III study (TAO, n >13,000) evaluated the use of otamixaban versus heparin plus Integrilin in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) with early invasive strategy planned. In the study, otamixaban demonstrated lower-than-expected efficacy and did not exhibit better risk-benefit than the comparator arm.

We are disappointed with the pipeline setbacks at Sanofi. We remain concerned about the generic erosion confronting most of Sanofi’s key drugs including Plavix, Avapro, Lovenox, Taxotere, Eloxatin and Xatral. The genericization of Avapro and Plavix is expected to negatively impact Sanofi’s business net income by around €800 million in the first half of 2013.

Sanofi is looking to combat headwinds by containing operating costs. Additionally, new product launches should make significant revenue contributions in the upcoming quarters.

Sanofi carries a Zacks Rank #3 (Hold). Companies that currently look attractive include Santarus, Inc. , Jazz Pharmaceuticals (JAZZ - Analyst Report) and Salix Pharmaceuticals (SLXP - Analyst Report). All three carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%